Long Term Investment in SYNGENE. Buy on any small correction for targets of 935.
Its not possible to share all fundamentals details here. Please check in NSC website. All major fund houses holding this stock.
Iffffffffffffff................ Thennnnnnnnnnnnnnn....... classic case if breaks black line.. question , will it confirm light blue line !!! pattern and not position is important here... i am bullish...
This is one bullish continuation chart pattern in a steady uptrend. The boundaries are well defined, several tests of the top boundary, I prefer those that break-out to All time highs. Target: 840.
Round bottom / Cup formation in progress.
HH and HL formation suggests upward momentum.
Broad RH and RS pattern adds more conviction on the long side.
Stop 525.
Target 650 plus.
The stock has formed a double top formation on weekly charts and looks bearish for short term.
There has been good volume on the day the stock made the high of 617.45 indicating sell off in the stock.
We can expect the stock to fall at levels of 500/490 and a reversal could be expected from then on. Make sure to keep a Stop loss at 618.
Syngene International daily charts show that it has been in a downtrend since 12-Dec-2016 making lower lows and lower highs.
Price broke above the downtrend resistance line in Sep 2017 and seems to have found support at levels of 440-450 (as observed in may 2017)
MACD & On balance volume indicators show bullish divergence as per the chart as observed in the month...
Syngene International Limited is a contract research company. The Company is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies. Its services include discovery chemistry and biology services, toxicology, pharmaceutical development, process development/manufacture of intermediates, active pharmaceutical ingredients and bio-therapeutics. Its services encompass integrated, discovery and development services for novel molecular entities (NMEs) across industrial sectors, including pharmaceutical, biopharmaceutical and biotechnology, among others. It specializes in conducting discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluation, and stability studies) and manufacturing (scale-up, pre-clinical and manufacturing supplies). It serves clients ranging from multinational corporations to start-ups.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
SYNGENE
